HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system

Pharmazie

Volumn 61, Issue 1, 2006, Pages 18-20

  Shen, Hai Rong ^a   Li, Zhong Dong ^a   Zhong, Ming Kang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; ATORVASTATIN; BUFFER; INDOMETACIN;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG ISOLATION; ENVIRONMENTAL TEMPERATURE; FLOW RATE; MALE; MICROEMULSION; NONHUMAN; PRECIPITATION; QUANTITATIVE ASSAY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET RADIATION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG DELIVERY SYSTEMS; EMULSIONS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDICATORS AND REAGENTS; MALE; PYRROLES; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 31144448096     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Asberg A, Hartmann A (2001) Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 1: 382-386.
2. Black AE, Hayes RN, Roth BD et al. (1999) Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 27: 916-923.
3. Black AE, Sinz ME, Hayes RN, et al. (1998) Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 26: 755-763.
4. Bullen WW, Miller RA, Hayes RN (1999) Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin; and para-hydroxy atorvastatin in human, dog, and rat plasma. J Am Soc Mass Spectrom 10: 55-66.
5. Cilla DD, Jr., Whitfield LR, Gibson DM et al. (1996) Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 60: 687-695.
6. Erk N, Altuntas TG (2004) Liquid chromatographic determination of atorvastatin in bulk drug, tablets, and human plasma. J Liq Chromatogr R T 27: 83-93.
7. Fukazawa I, Uchida N, Uchida E et al. (2003) Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol 57: 448-455.
8. Jacobson W, Kuhn B, Soldner A et al. (2000) Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 28: 1369-1378.
9. Jemal M, Ouyang Z, Chen BC et al. (1999) Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 13: 1003-1015.
10. Lea AP, McTavish D (1997) Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 53: 828-847.
11. Lennernas H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42: 1141-1160.
12. Malhotra HS, Goa KL (2001) Atorvastatin. An updated review of its pharmacological properties and use in dyslipidaemia. Drugs 61: 1835-1881.
13. Pouton CW (2000) Lipid formulation for oral administration of drugs: non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems. Europ J Pharm Sci 11: S93-S98.
14. Prueksaritanont T, Ma B, Tang C et al. (1999) Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br J Clin Pharmacol 47: 291-298.
15. Shum YY, Huang NJ, Walter G (1998) Development, validation, and inter-laboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices. Ther Drug Monit 20: 41-49.